Risk of ipsilateral breast event after surgical excision increases over time

the ONA take:

Women with ductal carcinoma in situ (DCIS) who undergo surgical resection without radiation have an increased risk of developing recurrence of DCIS or invasive disease, and that risk increases over time.

A prospective clinical trial sought to determine the 12-year risk of an ipsilateral breast event (IBE) in women with DCIS of the breast treated with lumpectomy without radiation. The results were presented in part at the San Antonio Breast Cancer Symposium.

Study participants were enrolled into two cohorts, not randomly assigned. Cohort 1 was 561 patients with low- or intermediate grade DCIS, tumor size 2.5 cm or smaller. Cohort 2 was 104 patients with high-grade DCIS, tumor size 1 cm or smaller.

Patients underwent excision of the DCIS tumor with a minimum negative margin width of at least 3 mm, and 30% of the patients received tamoxifen (not randomly assigned). An IBE was defined as local recurrence of DCIS or invasive carcinoma in the treated breast. Patients were followed for a median of 12.3 years. There were 99 IBEs, of which 51 were invasive.

Results show that 12-year rates of developing an IBE was 14.4% for cohort 1 and 24.6% for cohort 2; 12-year rates for developing an invasive IBE were 7.5% in cohort 1 and 13.4% in cohort 2. Study cohort and tumor size were significantly associated with risk for IBE. 

Risk of ipsilateral breast event after surgical excision increases over time
Women with ductal carcinoma in situ who undergo surgical resection without radiation have an increased risk of developing recurrence.
READ FULL ARTICLE From Ascopubs
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs